Knight to Present at the 16th Annual CIBC Eastern Institutional Investor Conference in Montreal
MONTREAL, QUEBEC–(Marketwired – Sept. 21, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present at the 16th Annual CIBC Eastern Institutional Investor Conference on Wednesday, September 27, 2017 at 3:25 pm ET at Le Centre Sheraton Montreal Hotel in Montreal. About […]
Knight Supports Crescita Trajectory
MONTREAL, QUEBEC–(Marketwired – Aug. 14, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has amended its secured loan agreement with Crescita Therapeutics Inc. (TSX:CTX) (“Crescita”), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products. Under the terms of the amended […]
Knight Reports Second Quarter 2017 Results
MONTREAL, QUEBEC–(Marketwired – August 10, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2017. All dollar amounts are in thousands except for per share amounts. All currencies are Canadian unless otherwise specified. Q2-2017 Highlights Revenues reached $2,840, an increase […]
Knight Supports Synergy with Third Secured Loan
MONTREAL, QUEBEC–(Marketwired – Aug. 9, 2017) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it has issued an additional secured loan of US$10 million to Synergy CHC Corp. (OTCQB:SNYR) (“Synergy”). The funds will be used to support product acquisitions as well as for general working capital purposes. The […]
Notice of Knight Therapeutics’ Second Quarter 2017 Results Conference Call
MONTREAL, QUEBEC–(Marketwired – Aug. 3, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its second quarter 2017 financial results on Thursday, August 10, 2017 prior to the market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to […]
Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence
PRINCETON, NEW JERSEY and MONTREAL, QUEBEC–(Marketwired – June 13, 2017) – Braeburn Pharmaceuticals, Inc. (“Braeburn”) and Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) has been accepted for review by Health Canada for PROBUPHINE® (buprenorphine subdermal implant) for the treatment of opioid drug dependence. […]
Knight to Present at the Jefferies Global Healthcare Conference in New York City
MONTREAL, QUEBEC–(Marketwired – June 2, 2017) – Knight Therapeutics Inc. (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer, is scheduled to present a corporate update at the Jefferies Global Healthcare Conference on Friday, June 9, 2017 at 1:00 pm ET at the Grand Hyatt Hotel in New […]
Knight to Present at the National Bank Financial Quebec Conference in Toronto
MONTREAL, QUEBEC–(Marketwired – May 31, 2017) – Knight Therapeutics Inc. (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that Jeffrey Kadanoff, Chief Financial Officer, is scheduled to present at the National Bank Financial Quebec Conference on Wednesday, June 7, 2017 at 3:00 pm ET at the Shangri-La Hotel in Toronto. About Knight Therapeutics Inc. […]
Knight Reports First Quarter 2017 Results
MONTREAL, QUEBEC–(Marketwired – May 11, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2017. All dollar amounts are in thousands except for per share amounts. All currencies are Canadian unless otherwise specified. “This quarter marked a […]
Knight Therapeutics Inc. announces voting results from the Annual Meeting
MONTREAL, QUEBEC–(Marketwired – May 10, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) announced today the voting results from the Annual Meeting of the Shareholders held in Montréal, Québec (“Meeting”). Election of Directors Each director nominee listed in the Management Information Circular dated March 21, 2017 (“Circular”) was elected as Director of the […]
